Monday, 3 June 2013

The addition of targeted therapy Avastin (bevacizumab) with chemotherapy can significantly lengthen the lives of women with advanced cervical cancer by close to 30%, according to research presented at the 2013 American Society of Clinical Oncology Congress. The finding is an important discovery in the fight against cervical cancer - the most common cancer in women under the age of 35. More than 3,000 women in the UK are diagnosed with cervical cancer annually, while 1,000 will die from it. Cervical cancer is normally treated with surgery, radiotherapy, and chemotherapy...


Post a Comment


Powered by Blogger.

ads 3

Popular Posts

ads 4

ads 5